e CIBER Fisiopatología Obesidad y Nutrición (CB06/03) Instituto de Salud Carlos III, Madrid , Spain SDS variation in IGHD patients and 15.9% of height SDS variation in controls. Conclusion: GH1 Promoter SNPs 6, 8 and 9 were associated with height and IGF-1 levels among patients, and SNPs 6 and 11 with height in controls.
matostatin, and by insulin-like growth factor 1 (IGF-I), the end product of GH's action.
Mutations in the genes encoding GH and GHRHR ( GH1 and GHRHR, respectively) can cause isolated growth hormone deficiency (IGHD) types IA, IB (OMIM No. 262400) and II (OMIM No. 173100). The frequency of GH1 and GHRHR mutations in IGHD patients varies between 0 and 32% among different countries [2] [3] [4] [5] [6] [7] . Thus, in the best of cases, mutations in the coding regions of GH1 and GHRHR are only detected in one third of the IGHD patients.
GH1 is located in the human GH cluster, in which 5 genes are situated on chromosome 17. Human GH ( GH1 ) lies at the 5 end of the cluster and is mainly expressed in pituitary somatotrophs. The remaining 4 genes, placental growth hormone ( GH2 ) and 3 chorionic somatomammotropins (CS1, CS2, and the pseudogene CS5 or CSHP1) , are only expressed in the placenta.
The expression of GH1 is regulated by a locus control region (LCR), located 14.5-32 kb upstream of the gene [8] and by the GH1 promoter. To date, 3 single nucleotide polymorphisms (SNPs) have been reported in the LCR [9] , while the GH1 promoter is highly polymorphic [9] [10] [11] [12] [13] [14] .
Although, in general, SNPs do not necessarily cause disease, they have been associated with susceptibility to diseases [15] [16] [17] and to environmental toxins [18] by affecting splicing [19] , allelic expression [20] , nonsense-mediated mRNA decay [21] or transcription factor binding [22] . GH1 promoter SNPs have been associated with height [9, 10, 12] , bone density, bone loss and fetal growth restriction [23, 24] . In addition, some GH1 promoter SNPs have been associated with breast and colorectal cancer [13, [25] [26] [27] [28] . Two promoter SNPs have been studied in relation to GH and/or IGF-I levels in patients with varying degrees of GH deficiency [11, 12] .
The Dutch Hypothalamic and Pituitary Gene Study is a nation-wide multicenter study investigating genetic and other causes of 'idiopathic' growth hormone deficiency in the Dutch GH deficiency population. In order to explain the variability in our IGHD patients' phenotypes and their variable response to GH treatment, we analyzed GH1 LCR/promoter sequence variations in IGHD patients and looked for associations of these variations with height, serum IGF-I levels and height increases during the 1st year of GH treatment. We compared the data with those of a healthy Dutch control group. Since Hasegawa et al. [12] related the SNP 'P1' in GH1 intron 4 (dbSNP 2665802) with height, GH and IGF-I levels, we also included this polymorphism in our analysis.
Patients and Methods
We included 62 Dutch Caucasian patients diagnosed with IGHD based on a scoring system including height SDS (HSDS), maximum GH levels, IGF-I and IGFBP-3 SDS without mutations or deletions in GH1 or GHRHR [29] . Patients' clinical data were available from the Dutch National Registry of Growth Hormone Treatment, where auxologic and laboratory parameters have been documented.
GH and IGF-I measurements were centrally performed in 1 laboratory with published reference values [30] for 80% of the patients. For the remaining 20%, the laboratory-specific reference values for IGF-I were used to calculate the SDS. We obtained approval from the medical ethics committees of all participating hospitals. Informed consent was obtained from all participating patients or their parents, if the patients were aged less than 18 years. Seventy-two healthy Caucasian Dutch young adults with a height SDS between -2 and +2 agreed to participate in DNA analysis as control subjects.
Genomic DNA, extracted from peripheral blood according to standard procedures, was used for direct sequencing of the GH1 LCR/promoter using an ABI 3100 Sequencer. A 1,231-bp fragment including the promoter of GH1 was amplified using forward primer 5 -GGGAGCCCCAGCAATGC-3 and reverse primer 5 -TCTGCCTGCATTTTCGCTTCG-3 by Touchdown PCR, including denaturation for 10 min at 95 ° C, amplification at 68-61°C decreasing the annealing temperature by 1 ° C every 2nd cycle and 25 subsequent cycles at 61°C, followed by a 7-min extension at 72 ° C. This fragment was sequenced by forward primers 5 -GGGAGCCCCAGCAATGC-3 and 5 -CTGTCTGGTGGGTG-GAGGTTAAA-3 , and reverse primers 5 -CACATTCAGAAG-CCCCAAAC-3 and 5 -ACCCAACTTGTCCTCTCTTTA-3 .
Since Hasegawa et al. [12] related the SNP 'P1' (IVS4 +90 T/A, dbSNP 2665802) in GH1 intron 4 with height, GH and IGF-I levels, we included this polymorphism in our analysis. P1 genotypes were available for patients who had participated in the genetic screening of the coding regions of GH1 and GHRHR as part of the Hypothalamic and Pituitary Gene Study [29] . In these patients, exon 4 and intron 4 had been PCR-amplified with forward primer 5 -CCGT-GAGTGGATGCCTTCTC-3 and reverse primer 5 -GTGAGT-TCTCTTGGGTCAGG-3 (annealing temperature 57.7 ° C), and the fragment had been screened by WAVE dHPLC at 62.1 and 62.6 ° C, which were shown to accurately detect the P1 variant [29] .
We used the GH1 gene nucleotide sequence obtained from GenBank (Accession No. J03071) as a control and we numbered the SNPs according to Horan et al. [9] . We obtained the reference LCR sequence from GenBank (Accession No. AF010280) and used LCR numbering according to Jin et al. [31] . Of the LCR/promoter SNPs, linkage disequilibrium represented by R 2 and D' was analyzed using Haploview [32] .
The associations between genetic and clinical parameters were analyzed by means of ANOVA and 2 tests using SPSS Version 11.0. Response to GH treatment was defined as the increase in HSDS during the 1st year of GH treatment. The normality of the distribution of all analyzed parameters was assessed with the KolmogorovSmirnov and Shapiro-Wilk tests. When expected cell counts for comparison of genotype frequencies between patients and controls were below 5, we used Fisher's exact test instead of the 2 test. Parameters that were not normally distributed were analyzed using the nonparametric Kruskall-Wallis test instead of ANOVA.
Results
All LCR/promoter SNPs conformed with the HardyWeinberg equilibrium according to a 2 test (p 1 0.05) except for promoter SNP 8 (p = 0.01). In contrast to Horan et al. [9] , we found that promoter SNP 2 was not polymorphic since all patients and controls carried the same allele. In patients and controls, there was a 100% linkage disequilibrium between LCR SNP 1 and 2, and there was a 100% linkage disequilibrium between promoter SNPs 4 and 5. Gene structure, sequence variation and linkage disequilibrium between LCR and promoter SNPs in our patients is shown in figure 1 . In patients and controls, promoter SNP 6 was strongly linked with LCR SNP1 (D' 0.96, R 2 0.92; fig. 1 ). In patients, promoter SNP 6 was strongly linked with SNP 'P1' in intron 4 of GH1 (D' 0.95, R 2 0.72; P1 genotypes were not available for controls, see methods section).
Height in cases and controls, and serum IGF-I levels in patients were normally distributed. Four promoter SNPs were related with height and IGF-I levels. An overview of these SNPs, their rs numbers, alleles and their relations with clinical parameters are shown in tables 1 and 2 , as well as figure 2 . de Graaff /Argente /van Meurs / Uitterlinden /Hokken-Koelega
Since genotype frequencies and clinical associations differed between IGHD patients and controls, we discuss the results of the IGHD patients and healthy controls separately.
IGHD Patients
The study population consisted of 43 male and 19 female IGHD patients, which is in accordance with a male predominance in the overall Dutch IGHD population. Mean ( 8 SD) age at testing was 15.6 8 6.4 years, mean age at the start of GH treatment was 5.7 8 2.7 years. At the start of GH treatment, height SDS was -3.1 8 0.9 and IGF-I SDS was -3.3 8 2.3. There were no differences in genotype frequencies, height SDS or IGF-I SDS between males and females.
We found significant differences in height and serum IGF-I levels between carriers of the different genotypes at individual promoter SNPs 6, 8 and 9 ( table 2 ) . LCR SNP1, promoter SNP 6 and intron 4 SNP 'P1' (IVS4 +90 T/A) were highly linked ( fig. 1 ) . In our population, there was no significant association between the individual intron 4 SNP and peak GH levels, HSDS and IGF-I levels as formerly described by Hasegawa et al. [12] (data not shown).
We did not find any relation between LCR/promoter SNPs and the 1st year response to GH treatment (data not shown).
Controls
The controls (27 males and 45 females) had a mean ( 8 SD) age at testing of 21.0 8 1.6 years and height SDS of -0.2 8 1.0. There were no differences in genotype frequencies or height SDS between males and females.
For promoter SNPs 6 and 11, height differed significantly between the carriers of the various genotypes ( table 2 ).
IGHD Patients versus Controls
We compared promoter SNP genotypes between IGHD patients and controls, and found that homozygos- a SNP identification according to Horan et al. [9] . b SNP position relative to GH1 transcriptional start site. c The most frequent genotypes in our study at the various promoter SNP sites are in accordance with the expected genotype when sequencing GH1 instead of any of the other four GH1 paralogue genes. d Only G alleles were reported by Horan et al. [9] and our study. e SNPs are 100% in linkage disequilibrium with each other. f Minor allele. de Graaff /Argente /van Meurs / Uitterlinden /Hokken-Koelega ity for the minor allele of SNP 9 was more frequent among patients than among controls (21% vs. 7%, p = 0.005, table 2). Since the minor allele at SNP 9 is associated with lower IGF-I levels in patients, this suggests this allele might contribute to impaired GH levels in IGHD patients. The promoter SNP 12 was tri-allelic with the major allele A occurring in controls in combination with 2 different minor alleles (AC and AT, frequencies AA 74%/AT 19%/AC 5%/TT 1%), whereas in patients, only the AT genotype was present. Among controls, there was no difference in height SDS between individuals with the AC and those with the AT genotype.
For promoter SNP 13, the minor allele was present in 4 of 72 controls (6%), whereas all 62 patients were homozygous for the major allele (p = 0.124). For the remaining SNPs, genotype and allele frequencies were similar for patients and controls.
Multiple Regression
The promoter SNPs that were associated with height and/or IGF-I levels in patients or controls (SNPs 6, 8, 9 and 11) were present in 23 different combinations ('SNP 6-8-9-11 genotypes'), of which 7 were present in at least 5% of the patients or controls ( table 3 ) . Only 48 controls and 44 patients carried these 7 most frequent combined genotypes; clinical data of the patients and controls with these genotypes are shown in table 3 .
Backward multiple regression showed that the 'SNP 6-8-9-11 genotypes' (numbered 1-7 according to table 3 ) explained 10.8% of the variation in IGF-I SDS in IGHD patients (adjusted R 2 0.108, p = 0.02). In controls, the 'SNP 6-8-9-11 genotypes' explained 15.9% of HSDS variation (R 2 0.159, p = 0.003).
Discussion
We analyzed GH1 LCR/promoter SNPs in IGHD patients without mutations or deletions in GH1 or GHRHR , and examined whether these SNPs were associated with height, serum IGF-I levels and response to GH treatment in order to explain the phenotypic variability present among IGHD patients. We compared patients' data with those of a normal control group and found that homozygosity for the minor allele of SNP 9 was more frequent among patients than among controls (21% vs. 7%, p = 0.005). The minor allele at SNP 9 was associated with lower IGF-I levels in patients, suggesting that this allele might contribute to impaired GH production in IGHD patients. Also SNP 6, 8 and 11 were related with height and IGF-I levels.
LCR SNPs 1 and 2, promoter SNP 6 and intron 4 SNP 'P1' (IVS4 +90 T/A; only available for IGHD patients) were highly linked. However, in contrast to Hasegawa et al. [12] , we did not find any significant association between the individual intron 4 SNP and peak GH levels, HSDS, * Only genotypes present in at least 5% of the patients or controls are shown.
1 Difference in genotype frequencies between IGHD patients and controls; p = 0.002.
and IGF-I levels in our population (data not shown), whereas we did find significant associations between LCR SNPs 1 and 2 and growth-related parameters, as well as between promoter SNP 6 and these parameters ( fig. 2 ). This suggests that the relation between the intron 4 SNP and growth-related parameters reported by Hasegawa et al. [12] , might actually be caused by its linkage with LCR SNPs 1 and 2 or promoter SNP 6, which, in our study, have stronger associations with growth-related parameters, but were not studied by Hasegawa et al. [12] .
We tried to combine promoter SNPs 6, 8, 9 and 11 into haplotypes. Although the result of the multiple regression based on these combined genotypes should be interpreted with caution due to the reduced patient number and subsequent power reduction, in our population the combined genotypes explained 10.8% of the variation in serum IGF-I levels in IGHD patients and 15.9% of height variation in controls. Although all patients had IGHD according to Dutch consensus criteria, certain genotypes were associated with a relatively mild phenotype.
The impact of individual SNPs can be explained by the fact that the regions in which they are located are important for transcription of GH1 . The LCR contains DNase I-hypersensitive sites located at -14.5 to -32 kb relative upstream to the GH1 promoter, where the transcription factor PIT1 binds in order to regulate GH1 transcription. Therefore, LCR SNPs may alter transcription of GH1. SNP 6 is located in the part of the promoter where nuclear factor 1 binds [33] . Binding of nuclear factor 1 to the nuclear factor 1 binding site is necessary for transcription, and variation at this site may alter expression of GH1 . Promoter SNP 8 is located in the proximal PIT1 binding site and promoter SNP 9 is located in the region corresponding to the vitamin D receptor response element. Disturbed binding of PIT1 and the vitamin D receptor to the PIT1 binding site and vitamin D receptor response element, respectively, may alter transcription and, thus, expression of the GH1 gene. Both SNP 8 and 9 were shown in vitro to interact with nucleic acid binding proteins, and alternative alleles exhibit differential protein binding [9] ; SNP 9 showed protein interaction only for the G allele, not the T allele [9] . This is in accordance with our findings in vivo that patients homozygous for the T allele have very low IGF-I levels ( table 2 ). For SNP 8, Esteban et al. [10] demonstrated a lower HSDS in carriers of the alternate allele in a control normal height adult population; Giordano demonstrated a diminished transcriptional activity for the alternate allele [11] . For SNP 9, Giordano demonstrated diminished GH secretion in alternate allele carriers [34] . SNP 11 is located in the transcriptional start site of GH1 ; therefore, variation at this site may alter efficacy of transcription, leading to varying levels of GH1 expression. Probably, the effect of the promoter SNPs is the sum of individual SNP effects and effects based on combinations with other SNPs. Variation at 1 individual SNP site can cause altered binding of the corresponding protein. This altered binding can in turn affect the binding of a 2nd protein at another SNP site, but the extent to which the binding of this 2nd protein is affected will also depend on the variation at the 2nd SNP site.
Associations between LCR/promoter SNPs with height and IGF-I levels are likely to be mediated by GH levels in serum, which may vary due to altered expression of GH1 . Although the variation in IGF-I SDS between the different genotypes was largely in accordance with the variations in peak GH levels obtained during GH stimulation tests, the association between the genotypes and peak GH levels was not significant ( table 3 ). The fact that IGF-I levels are associated with LCR/promoter SNPs, whereas stimulated GH levels are not, may be explained by the fact that forced GH secretion during a stimulation test does not always reliably reflect the spontaneous GH secretion pattern. Due to the fact that it reflects spontaneous daily GH secretion, serum IGF-I is considered a more reliable indicator of spontaneous GH secretion than GH peaks during stimulation tests [35] [36] [37] . Therefore, although LCR/promoter SNPs are not significantly related to peak GH levels obtained during stimulation tests, the relation of these SNPs with height and IGF-I levels is probably mediated by altered spontaneous GH secretion.
The LCR/promoter SNP genotype frequencies and clinical associations differed between IGHD patients and healthy controls. These differences may be explained by the fact that certain genotypes could be beneficial for processes that take place in IGHD patients, but not in controls, due to the altered GH/IGF-I status.
Although all controls had a height within the normal range, the lowest height SDS were found in patients heterozygous for promoter SNPs 6 and 11. This association with shorter stature was specific for the heterozygous state, since controls homozygous for the minor allele had a higher HSDS. The finding that the heterozygous state is associated with a certain phenotype and differs from the 2 homozygous states, has been previously reported and is the subject of research and discussion [9, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . Heterozygous advantage or disadvantage of promoter SNPs may be explained by allele-dependent regulation of gene expression. A key process in allele-dependent regulation of gene expression is trans -regulation, which means that an enhancer from 1 allele acts in trans to activate transcription from the promoter of the 2nd allele [45, 46, 48] . Transcription factors can bind 2 DNA molecules simultaneously, functioning as a protein bridge and mediating enhancer-promoter communication between 2 homologues [49] . Trans-regulation, i.e. the interaction of 2 alleles in trans, might explain advantages or disadvantages of heterozygosity as found in several studies [50, 51] and in SNPs 6 and 11 in our study.
Recently, a map of GH1 promoter SNPs in a Spanish adult control population with normal height was reported [10] . The investigators found 11 SNPs in the promoter region, of which 2 (corresponding to SNPs 8 and 14 in our study) were related to HSDS. The studied promoter SNPs accounted for 6.2% of adult height determination in the adult Spanish population. Horan et al. [9] studied GH1 LCR and promoter SNPs in relation to height, and found that 3.3% of the variance of adult height was explained by promoter haplotypes. Our study largely analyzed the same set of promoter SNPs as studied by Horan et al. [9] and Esteban et al. [10] , but instead of including all promoter SNPs in the combined genotype analysis, our study focused on the SNPs 6, 8, 9 and 11, as they were individually associated with height or IGF-I levels. Our study analyzed combined SNP 6-8-9-11 genotypes with frequencies above 5%. These most frequent combined genotypes were present in 73% of the patients and 68% of the controls. Although genotype numbers were small and results should be interpreted with caution, SNP 6-8-9-11 genotypes explained 10.8% of IGF-I SDS in the IGHD patients (p = 0.02) and 15.9% of HSDS in controls (p = 0.003). Such a strong association between promoter SNPs with height and serum IGF-I levels has not previously been described, and this may be due to the different approach and the number of SNPs included in the combined genotype analysis. By limiting the number of SNPs included in the combined genotypes to those that were individually associated with height or IGF-I, we have narrowed the window of promoter SNPs that seem clinically relevant for GH expression, height and IGF-I.
In conclusion, homozygosity for the minor allele of SNP 9 was significantly more frequent among patients than among controls. Since this minor allele at SNP 9 was associated with lower IGF-I levels in IGHD patients, our data suggests that this allele might contribute to impaired GH production in IGHD patients. Apart from SNP 9, SNP 6, 8 and 11 were also related with height and IGF-I levels.
